Abstract
Prospective validation of strategies to reduce mortality and morbidity in women with BRCA1 and BRCA2 (BRCA1/2) mutations is needed. There are no randomized controlled trials of different screening or prevention strategies for either breast or ovarian cancer risk reduction in high-risk women. Most studies of cancer risk reduction in women with BRCA1/2 mutations have relatively short follow-up, and few have overall mortality as an endpoint. However, there may be substantial benefits for women with BRCA1/2 mutations when an individualized evidence-based prevention strategy is provided by a team with experience in managing hereditary breast and ovarian cancer risk [1].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
